Evidence map›Paper›PMID 39448194›Full record

ReviewAdvances in parasitology2024

The proteasome as a drug target for treatment of parasitic diseases.

Lawrence J Liu, Anthony J O'Donoghue, Conor R Caffrey

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Advances in parasitology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Enhancing schistosomiasis drug discovery approaches with optimized proteasome substrates.Protein science : a publication of the Protein Society · 2025
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Lawrence J LiuCenter for Discovery and Innovation in Diseases (CDIPD), Skaggs School of Pharmacy and Pharmaceutical Sciences, University of California, San Diego, CA, United States; Department of Chemistry and Biochemistry, University of California, San Diego, CA, United States. Electronic address: ljliu@ucsd.edu.
Anthony J O'DonoghueCenter for Discovery and Innovation in Diseases (CDIPD), Skaggs School of Pharmacy and Pharmaceutical Sciences, University of California, San Diego, CA, United States.
Conor R CaffreyCenter for Discovery and Innovation in Diseases (CDIPD), Skaggs School of Pharmacy and Pharmaceutical Sciences, University of California, San Diego, CA, United States.

Funding

Proteasome inhibitors against mucosal protozoan pathogensR01AI158612 · NIAID · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI ECKMANN, LARS, O'DONOGHUE, ANTHONY JOHN · 2021 to 2025
$3.2M
The catalytic core of the proteasome as a drug target to treat Human African TrypanosomiasisR21AI171824 · NIAID · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI CAFFREY, CONOR, O'DONOGHUE, ANTHONY JOHN · 2022 to 2023
$435k
Selective proteasome inhibitors for trichomoniasisR21AI146387 · NIAID · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI ECKMANN, LARS, O'DONOGHUE, ANTHONY JOHN · 2019 to 2020
$433k
Exploring the proteasome as a new drug target to treat schistosomiasisR21AI133393 · NIAID · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI O'DONOGHUE, ANTHONY JOHN · 2017 to 2018
$426k
Brain Penetrant Microtubule-Stabilizers to treat CNS-invasive parasitic diseasesR21AI133394 · NIAID · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI BALLATORE, CARLO, CAFFREY, CONOR · 2018 to 2019
$426k
NIAID NIH HHS R01 AI158612NIAID NIH HHS R21 AI133393NIAID NIH HHS R21 AI133394NIAID NIH HHS R21 AI146387NIAID NIH HHS R21 AI171824
6 · The paper itself

Abstract

The proteasome is a proteolytically active molecular machine comprising many different protein subunits. It is essential for growth and survival in eukaryotic cells and has long been considered a drug target. Here, we summarize the biology of the proteasome, the early research relating to the development of specific proteasome inhibitors (PIs) for treatment of various cancers, and their translation and eventual evolution as exciting therapies for parasitic diseases. We also highlight the development and adaptation of technologies that have allowed for a deep understanding of the idiosyncrasies of individual parasite proteasomes, as well as the preclinical and clinical advancement of PIs with remarkable therapeutic indices.

Indexed as

Parasitic DiseasesProteasome Endopeptidase ComplexProteasome InhibitorsAnimalsHumansProteasome Endopeptidase ComplexProteasome Inhibitorsdrug devlopmentinfectious diseaseparasiteproteaseproteasomeproteasome inhibitors

Identifiers

PMID39448194
PMCPMC13128279

What Socratic holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.